Phenotyping Genetic Risk for Type 2 Diabetes
Recruiting · NCT04024631 · Interventional (participants receive a specific treatment) · Lead sponsor: University of Pennsylvania
View the official record on ClinicalTrials.gov →Interventions studied
75g glucose beverage (Glucola, Trutol, or similar brand)DXA, whole body
What this trial is about
This study tests the hypothesis that non-diabetic individuals with a high genetic risk score for type 2 diabetes have impaired glucose tolerance and insulin resistance compared to those with a low genetic risk score for type 2 diabetes.
Who can take part
Age range
10 Years to 70 Years
Sex
All (male and female)
Healthy volunteers
Yes - healthy volunteers may be accepted
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Age 10-70 years
- Prior participant of the UPenn Biobank or Center for Applied Genomics Biobank and agreed to be recontacted for future research.
- Adults with BMI 25kg/m2 or higher, children and adolescents with BMI 85th percentile or higher
Exclusion criteria
- prior diagnosis of type 1, type 2, or secondary diabetes
- use of medications that would impact glucose and insulin response such as steroids, metformin or other anti-diabetic medication
- acute illness that may impact insulin and glucose dynamics
- pregnancy
- hypothalamic obesity or related genetic disorder of metabolism
- recent systemic chemotherapy use
- gastrointestinal impairment or surgery that may impact absorption
- anemia
- major organ system illness or any underlying condition requiring regular medication or treatment that could make implementation of the protocol or interpretation of the study results difficult
- inability to comply with study protocol
Where it is running
2 locations listed across 1 US state.
- Childrens Hospital of Philadelphia - Philadelphia, Pennsylvania, United States
- University of Pennsylvania - Philadelphia, Pennsylvania, United States